Clinical Trials Logo

Mesotheliomas Pleural clinical trials

View clinical trials related to Mesotheliomas Pleural.

Filter by:

NCT ID: NCT03907852 Active, not recruiting - Ovarian Cancer Clinical Trials

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Start date: April 15, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently evaluate the efficacy of gavo-cel, with and without immuno-oncology agents, in patients with advanced mesothelin-expressing cancers, with overall response rate and disease control rate as the primary Phase 2 endpoints.

NCT ID: NCT03760575 Recruiting - Clinical trials for Mesotheliomas Pleural

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Start date: January 10, 2023
Phase: Phase 1
Study type: Interventional

The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural mesothelioma (MPM).

NCT ID: NCT03475953 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

REGOMUNE
Start date: May 4, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial). Assessement of the efficacy and safety of a low-dose of regorafenib (80mg/day) with avelumab in patients with advanced or metastatic colorectal tumors.

NCT ID: NCT03054298 Active, not recruiting - Ovarian Cancer Clinical Trials

CAR T Cells in Mesothelin Expressing Cancers

Start date: April 6, 2017
Phase: Phase 1
Study type: Interventional

Phase I study to establish safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells with or without lymphodepletion.